- Oral presentation will feature HS135, the Company’s Phase 1 novel Activin and GDF inhibitor
- Selected to present during PAH focussed ATS Mini Symposium
35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA, USA (May 17 – 22, 2024).
The presentation will feature data on HS135, the Company’s Phase 1 novel Activin and GDF inhibitor, in models of Pulmonary Hypertension and will form part of the thematic Mini Symposium: Lessons learned from large scale clinical trials in PAH.
Details of the presentation are as follows:
- Date: May 19th, 2024
- Time of presentation: 9:39 AM – 9:51 AM
- Location: San Diego Convention Center
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
